Why Everyone is Wrong About Cannabis Consumption with Len May

Are you frustrated with the one size fits all approach to health and wellness? Do you wish there were more personalized solutions based on your unique genetics and biology? If so, you're in the right place. My guest today is Mr Len May, founder and CEO of EndoDNA, a company using advanced DNA testing and AI to provide customized cannabis and wellness recommendations for medicinal use. Mr May shares how understanding your genetic predispositions can help determine the right cannabis and supplement protocols for your needs. That's right. The answer is in your DNA, so tune in to get the details. Welcome to Pivoting Pharmacy with Nutrigenomics. Part of the Pharmacy Podcast Network, a must-have resource for pharmacist entrepreneurs seeking to enhance patient care while enjoying career and life. Join us as we pivot into Nutrigenomics, using pharmacy and nutrition for true patient-focused care. Explore how to improve chronic conditions rather than just manage them. Celebrate entrepreneurial triumphs and receive priceless advice. Align your values with a career that profoundly impacts patients. Together, we'll raise the script on health and pivot into a brighter future. Before you listen in, I want to thank our listener of the week, allsportsmom21, who says it's refreshing to hear another perspective to help in patients and educate in patients to learn about how to heal themselves and get healthy. Thank you, allsportsmom. It's refreshing to me that you found our podcast refreshing and helpful. The essence of pivoting pharmacy with Nutrigenomics is to guide listeners like you and shake it off the traditional shackles of pharmacy practice, moving towards a holistic, patient-focused approach. We believe in sharpening the tools of self-education and self-healing, not just for us as healthcare professionals, but for our patients too. So please continue to join us on our collective exploration into fresh avenues of patient care. So thank you for your review and remember, when you leave us a five-star review, you'll get the chance to be featured as our next listener of the week and I'll give you a shout out right here on the show. Hello, hello and welcome to episode 16 of Pivoting Pharmacy with Nutrigenomics. I'm Dr Tamar Lawful, doctor of pharmacy and nutritional genomics specialist. You know there are moments in our lives that challenged the way we see things, that make us question the status quo. Well, this is one of those moments. We're about to challenge some commonly held beliefs about cannabis consumption Intriguing, right. I'm beyond thrilled to dive into this topic with you All right, so you've heard the buzz on cannabis restorative therapeutic effects, a natural alternative Sounds like the perfect remedy, right, but how does someone find the right product or dose. The truth is the one-size-fits-all approach, isn't it? What if I told you you can personalize the medicinal cannabis journey much like your favorite cup of coffee Stirring, isn't it? On this groundbreaking episode, we're debunking the myths and taking personalize to a whole new level. Ever heard of DNA testing for cannabis? It's like 23 and me, but for your cannabis needs. So let's see what this is all about in today's episode with Mr May, ceo and co-founder of Endocana Health Incorporated, who joins us with a rich 25-year history in cannabis and genomics. He has paved a luminous trail in patient-centered care. As a certified medical cannabis specialist in medicinal genomics and holding a master's of medical cannabis, mr May has an in-depth knowledge of genomics, cannabinoids and terpenes and their interaction with the endocannabinoid system as well. He is a thought leader in medicinal genomics and affirms the power of personalized healthcare. This enlightening conversation could be the catalyst you need to redefine your role in pharmacy. So let's dive right into the under-bridge world of nutrigenomics and cannabis. This is sure to ignite your entrepreneurial journey. Let's listen in. Welcome, mr May. Thank you for joining us on the Pivoting Pharmacy with Nutrigenomics podcast. Now can you give our listeners a little bit? Tell us about you.

Well about me. Well, how long do we have? I was actually born in a country called Lithuania and immigrated when I was about six years old, grew up in Philadelphia and moved to Los Angeles about 16 years ago. But I was the kind of kid that would sit in class and I get all these different thoughts like Windows and your computer will be open my head, sort of daydreaming, and a teacher will call on you and be like what? Now Back to present. So I got diagnosed with ADD and I was put on all kinds of prescription medication and I can't say it didn't work whatever the definition of work is, but they all kind of numb me. So it took away any feeling of self. And I was hanging out with some kids, just I guess in the beginning of high school, maybe the end of my eighth grade, ninth grade somewhere around there, and they asked me to smoke a cigarette with them. I'm like cool, hanging out with the cool kids, we'll smoke a cigarette and I never questioned why they only have one cigarette. So they ended up passing the cigarette to me. I took a drag of that cigarette and kind of taste weird. I took another drag and kind of coughed a little bit and they're all laughing at me. So they have cannabis inside the cigarette and when I went to class the windows in my head sort of narrowed. They disappeared. I could focus. Okay, this is odd. So then every single time they were consuming cannabis. After that it did the same thing. I never mentioned anybody that we would consume chronicler recreationally or whatever ear and ears and would get older. My parents didn't care for that that much, so they would get upset with me and at the end of the day, at the end of high school, they end up kicking me out, actually calling the cops, I mean trying to have me arrested. The irony of the story is that they consume formulations that my company produces now, and all of these are genetics tests. So I can't kind of full circle. But that started my trajectory into really understanding the plan and how it affects your body and what your end of cannabinoid system is. So I became an activist. I was the president of the cannabis action network legalization back in the mid 90s, and then my ex-wife, who was my girlfriend at the time, said I have to get a real job. So I went to work for Price Waterhouse. I was going to physical therapy school. That was my sort of background, thank you. Then I was a consultant for a venture capital company. Then I was a commercial real estate broker for a while, moved to Los Angeles, was still sort of down in real estate and then these guys came in and wanted to open an alternative pharmacy. Like that's interesting, what do you really want to do? And it was dispensary, so I helped them and they offered me a partnership and I ended up being a partner in five different dispensaries under the same brand. But my passion has still been the therapeutic properties of the plant. So I was always trying to figure out why two people consumed the same chemical variety and have a completely different experience. So I really started focusing on plant genomics. I found a video by a gentleman named Kevin McCartan, who was the first person in the genetic sequence cannabis, and reached out to him and learned a lot about plant genetics, and their parent company was a pharmacogenomics company and I still got really involved in the human genetics. So anyway, that's my long-winded story about my background and I can dive into any more specifics.

I like it. So, from your accidental experience with cannabis and how it impacted your ADED to now making it a company where we're focusing on being more specific, you're focusing on genetics and a different strains that would be more beneficial for people based on their genetics. From looking at your background, you've mastered the workings of the endocannaboid system and the interplay with genomics. So how might this knowledge actually empower pharmacists who want to redefine their role and deliver a more personalized approach to health?

Well, I just believe that everything is a personalized approach to health and wellness. So we've been sort of doing this cookie cutter approach for way too long. Take two of these and call me well, why should I take two of these? Why should I take four, or why should I take one? Maybe I'm an ultra rapid metabolizer, maybe I'm a poor metabolizer. So the way that we sort of look at this is the way that we met with the FDA and they asked us what is the purpose of your test? And we told them to help people either mitigate or avoid a possible adverse event. It's wonderful. So that's the goal and what we do is focused on that. First, it's to be able to help people, guide people to an experience that is going to be safe First, efficacious is. Second, we want to make sure that people consume things that are not going to trigger a possible adverse event. So when I look at this, we genotype somewhere around 700,000 genetic biomarkers and what we look at is everything is directly or indirectly associated with the endocannaboid system and understanding how the endocannaboid system works because it touches every other system in our bodies and we understand how our endogenous endocannabids, what are the neurochemicals that we produce ourselves and how does that affect an individual in different types of activities or different types of work they do or stress things of that nature. So people that consume phyto-cannabinoids that actually can bridge those gaps, they may be naturally deficient in themselves. Well, if they consume something that is not really aligned with them, they can actually trigger the adverse effect prone to stress reactivity and has a predisposition for that. And they consume higher THC, which has a very narrow therapeutic window. With certain terpene profiles, which are essential oils in the plant, they can actually trigger the predisposition and epigenetically express that stress reactivity, instead of the opposite of what they really wanted to do. So our goal is to be able to guide people and pharmacists are very comfortable with pharmacogenomics Right, so you're looking at how things to interact. So think about this as another supplement they can take a look at and see how it would interact in order for people to avoid those adverse events. And the kicker is now that we sort of have a secret sauce like this is the area that I should be in. These are cannabinoid terpenes are more aligned with me. Now this is how I should be dosing, based on my metabolic function, and we're looking at specific cytokine. P450 markers are associated with cannabis, and now we can actually start matching people, the products, based on the certificate of analysis and test results of products, and then seeing how closely those products match their suggest ratios. And, the best part about it, there's a feedback loop so we actually have people report outcome and also integrate wearable devices so we can start building data. So the first thing we start is safety, but now we want to make sure these products are efficacious, and by efficacious is there is a reduction of blank, whatever it is, or there's an increase of whatever that is, and we use clinical value, that assays like the peg three for pain, etc. To be able to document all those things, to create what we consider the world's largest observational study on efficacy using these substances as well.

Wow, that's amazing. So Clarify you're looking at these genomic factors from the client or patient as well as the phytonomics and matching them.

Yes. So the way that it works is we get DNA data two ways. Number one is our patented endo-DNA test. So the patent is and I'm going to kind of paraphrase it it's the use of DNA to make recommendations associated with the endocannabinase system, presented through a graphical user interface. And the PTO approved our AI machine learning algorithm that we've been using since 2018 as well. So we extended that patent and the machine learning starts making predictive inferences based on buckets, et cetera. The more critical mass that we have, the better hone in on suggestions that we can make. So first is our endo-DNA test. It is HIPAA and GDPR compliant. You can get it at your doctors, you can get online. You would swab the inside your cheek, you'd register that and you would send that sample to our lab. It'll take two to four weeks to get your results and then you would get your results in your personalized portal and I'll explain sort of what we're looking at there. And the second thing is if somebody's already taken a DNA test, like 23Me or Ancestrycom or any other DNA test, you can take the raw data from that test, upload it to our portal. We'll translate that and provide you a report within an hour that shows you basically the same kind of information. There will be some missing polymorphisms that they don't cover, but it'll give you at least 50% coverage. And the first thing we look at is every single symptomatic condition, what people consume cannabis for and where your genetics play a role, so cognitive function, immunohealth, pain and nausea, sleep mood. And then we look at the specific genes, specific genetic biomarkers, that are associated with their symptomatic conditions. We look at possible predispositions to adverse effects. So some people are predisposed to things like psychodomatic effects, like COSES-like effects, so we actually show everybody what their predisposition is and how to sort of navigate those sharp corners to make sure that you don't step in a pothole that's in the room. And then, as I said, the next thing we look at is drug-to-drug interaction. So right now we have over 200 different medications that we pull in and we see if any of those have a documented interaction and every single report that we have must have a peer-reviewed reference from an essay that was done PubMed or equivalent to PubMed. Talk about drug interaction also. The second part is metabolic function. So we look at three specific cytokone P450 pathways where cannabinoids are, where the enzymatic pathways are, so CYP2C9 for THC, cyp2c19 for CBD and CYP3A4 for CBD and THC together. That's why one of the reasons why people have different experiences when they use a whole plan versus the individual components as well.

Oh, interesting. I think it's also great that you make it usable for everyone. If they already have their DNA through another company, they can upload it, although they won't get all the polymorphisms to be run. So how do you approach a situation where you find that someone might be more prone to psychosis with the use of cannabis? Then what would you do?

So this is for informational purposes only. The FDA does not approve anything that has to do with the endocannabinary system. It's a rescheduling of cannabis. So provide that information. If they would like to speak to a health care professional, we can actually facilitate that through telehealth. If they would like to have a conversation with their own health care professional, they can do so as well. They can mitigate or maybe avoid hired THC products then can trigger psychosis in those people. Hired CBD, as the platform will probably suggest very low THC, higher CBD, different terapine profiles. But we empower you with information to make your own decisions. So we don't have a clinical filtration of any sort of way. We don't prescribe and the only thing we do is provide you sort of your own personalized GPS so you can make more informed decisions with your fight of cannabinoid use. And then you can take that information and take whatever actually you think is relevant for you. But I would say that based on thousands and thousands of people that we looked at most people that THC really does have narrow therapeutic window. When you take too little there's very little efficacy. When you take too much it does trigger a lot of those adverse effects Because you have sort of free radical anandamide, which is the endogenous version of what we consume THC Delta 9, it binds your CB1 receptors in our brains and our central nervous system and releases anandamide. So if you have too much anandamide, you actually have an immunoresponse to that which can trigger a lot of these adverse effects. So we want to make sure that people have really transparent information. And, by the way, this is not just with fight of cannabinoids. We're actually moving right down to whole genome sequencing. So we're moving to 64 million genetic biomarkers. So looking at personalized precision wellness and it's looking at your entire genome. Looking at supplements, interactions what are the supplements and drug interactions what are the things we have a supplement for? We have a skin report. We have a mental health report. We have a report on women's health. We're working with women's health specialists to look at predispositions to menopause, perimenopause, postmenopause. What are the symptoms associated with this person's individual menopause? Are they more prone to mood swings? Are they more prone to different things? And we can actually have that communication, because the idea is to have a collaborative experience with your health care professional. Both look at the same information and you can jointly make better form health care decisions for the individuals. That's where our goal is.

I love it. I love it. Mr May, that is pretty awesome. We talk about precision Like why guess, why guess, when you have these tools that can definitely help streamline the care health care for patients and clients. I absolutely love it. So you've been steerheading the legislation or been part of legislation around cannabis. Can you share what your journey has been like with that? Was there a turning point along this process?

Well, I brought up that I used to be the president of the Cannabis Action Network, so a lot of it is in a way. And I had a rally in Independence Hall in Philadelphia. This was back in 1993. And Independence Hall is where the Liberty Bell was. Constitution Declaration of Independence, by the way, written in hemp paper. But my keynote speaker was this lady named Elvie Musica, and Elvie was one of the at the height of the program. There were 16 people, but I think there was four left that were getting legal cannabis from the United States government under this program. There was cultivated in Mississippi with a USDA label on it. So think about it this way it's a Schedule I narcotic, no medicinal purposes. The federal government did have a patent for it as a new protecting, cultivates it in the University of Mississippi for research purposes and actually allowed 16 people to have this plan. OK there's some irony there. I don't know. It's not for me to decide why, I'm just sharing it with the audience and everybody can go on Google and research it. So LB was one of those people that would get medically prescribed cannabis. So cannabis was cultivated in Mississippi central location, rolled into they looked like cigarettes and metal jar with a USDA label on it, and she opened this jar and lit up her cigarette joint in federal rangers because it depends all this federal property. And no, we did anything because she had federally legal cannabis. Now that was an exciting moment. This is 1993. Pennsylvania didn't legalize until 2020. I think so it took a very, very, very long time. Now moved to California. There was this Prop 215 and SB420, which allowed for the use of cannabis in this collective. And when they say collective, basically it was not for profit entity. So if you are the cultivator, you're cultivating for me, for my medical condition, and it costs you $30 to cultivate it. Now we have an exchange you provide me a product, I give you $30, you didn't make any profit, but I got my medicine and that was the model until you know when recreational a few years back. So as we're talking policy, there's two different types of policies. There's the policy for the states themselves, then there's the federal policies overarching and there's a huge disconnect. Now the hemp bill actually helped to alleviate some of this, because 0.3% THC products under the hemp bill that are hemp-thrived can be extracted and can be shipped throughout the country. So people are getting, you know, those kind of products. The challenge is that people who have conditions that require high amounts of THC can't, and there's still those, you know, refugees that are going from state to state. That's one thing. Number two the federal government has been looking at legalizing cannabis for years and lately one of their conditions is they're looking at rescheduling cannabis. So when you reschedule cannabis to a schedule three or four, you will. It's still a controlled substance. You still need to be able to have some sort of prescription or, even if it's OTC, you have to go to a pharmacy to show your license and your. I don't know if dispensaries are going to be the future of dispensing medicine, with no offense to bug tenders but people who are unqualified to give any medical suggestions, providing people with medicine that they really need. Now, georgia is the first state that actually approved cannabis to be actually sold through a pharmacy, which I believe is a crystal ball to look in the future, because that's something that I feel you know. You have qualified pharmacists, you have people who understand how certain drugs interact and, yes, cannabis is absolutely a drug how it interacts with individual individualist bodies. So to me, I believe that there's going to be a shift at some point with federal policy. When I met with the FDA about a month ago in Chicago, we were at a conference called Benzinga Conference. I was speaking there and some of the members of the FDA and they said one of the toughest things they have right now is to be able to look at safety of this product because there's so many derivatives that are coming out Delta 8, delta 10, they're not sure. These isomers they're creating from hemp, which is you know, these loopholes in the law, how safety are you know? And that this is the whole approach that I feel the federal government needs to take. First is to create standards. Think about this way if I'm in California and I have a cannabis product let's say it's a one-to-one with a certain terapine profile well, if I go to Pennsylvania, I can't get that same product. We have complete inconsistencies. I should be able to get my vitamin, my supplement, the same way at a vitamin store, no matter where I go. The labels should be identical, the testing guidelines should be identical, and that's where the federal government has to come in and create these overarching regulations to make sure that we have safe and efficacious products in every one of our states.

Right, I agree, it would definitely have to be safe and efficacious. But then who makes it? Is going to be another type of pharma company that's involved in this, so that it is standardized across the nation. You mean, who actually manufactures? Who manufactures? Yeah?

We have CGMP guidelines right. So if a pharmacist doesn't have to manufacture supplements but supplements actually have guidelines, that they should follow throughout. So there are medical food products. There is a category of supplements that is approved by the FDA. There are supplements with specific labels that are approved by the FDA. So I'm saying that if they have licensed manufacturers that are making supplements, licensed manufacturers can also make phyto-canabinatory products, as long as they adhere to the standards, not only GMP, but there's also standards on pharmaceutical drugs that should be taken and who manufactures them should be the people that are approved to follow those specific guidelines that have an oversight by the FDA.

That's my view, 100%, 100%. I love it From standing in Independence Hall. In 93, I went to college in Philadelphia. I grew up on the East Coast as well, so very familiar with the area. Yeah Temple was around the corner, so where you are now. Are you able to shed some light on any emerging trends in cannabis science, if any, at this time and potential pivots that our audience could take into that?

Well, I think the trend that's happening now that I see is there's this whole division of recreational versus medicinal. I'm not a believer in recreational. I believe that every single product you put in your body that has an altering effect is a therapeutic product in some way. Whether you smoke a joint or eat a gummy instead of drinking your whiskey late at night, or whatever that is, you're still altering your mood and should be seen as that type of substance. What I've been seeing from a research standpoint is the pharmaceutical industry is moving deeper into research on cannabinoids and they're moving into research on cannabinoids for specific conditions and specific receptor binding responses. What I mean by that is, pharmaceuticals don't understand or are uncomfortable with whole plant because they can't really see which one of the molecules is actually creating the benefits Jazz pharmaceuticals actually has. Epidialix is the only product that's actually approved by the FDA for a form of childhood epilepsy. The future of drug development is looking at receptor binding isolated molecules, whether it's one, two or maybe up to four different molecules that bind to those receptors for specific conditions. So there are studies. We're involved in six clinical trials right now. One of them is Harvard Medical, with three going over Chum in Montreal, and they're all for specific conditions with a specific molecule. So that's the future of pharma where it's going Now. Cannabis itself is still the smokable products are still the highest selling products, but now edibles and gummies are starting to catch up a little bit. So a matter of convenience. People don't want to smoke in their lungs, they're out. They may want a gummy, but we're seeing a tremendous amount of increase of adverse effects because of this trend of edibles. And the reason why is, I feel, first of all, since we still don't have guidelines on dosing, we're not sure how much is actually in this edible, how am I metabolizing that and what is it triggering for me? So there's this trend of people that have. Some people have cannabinoid hyperemesis syndrome. I'm going to ask you about that. We actually completed a study on PubMed on cannabinoid hyperemesis syndrome our boss with Dr Ethan Russo and a couple other people, and we found that there are about five different genetic biomarkers that were associated with our cohort. There is something to be said by poor metabolizer stress markers and this connection through the vagus nerves, which should be a cyclic vomiting syndrome as well. So that's our study. It was a small study which needs to be expanded to a larger cohort, but that's what we found. So our goal was not to be able to diagnose anybody with CHS. It was to find is there a genetic pattern in a cohort? That's what we reported on. So, because we don't know how to talk about an effect like, here's a product for a certain effect. So what people are gravitating towards is these higher THC products, and that's why I think we actually fall into these traps of adverse effects. So we're on this hamster wheel of trying to address an adverse effect for somebody, somebody that's taking 100 milligrams of THC, having this effect, triggering the stress reactivity, triggering the PTSD, triggering maybe a psychotic episode, and then being reported as oh, this is the adverse effects of consuming cannabis. Well, if I take a handful of pills that are prescribed to me that I should only be taking one, but I took a handful of it, it's the same thing. You have an adverse effect because you took too much and forget even prescription medication. What if you went out on a night and you had a bunch of tequila? Man, you're going to feel pretty crappy the next day. You're not going to say man, that Jose Cuervo, whatever that tequila company. They really try to do this to me. They gave me way too much. No, you're going to blame yourself and saying next time I'll think better on how to limit the amount. And this is this economy. It makes no sense you took too much and now you have an adverse effect and, yes, that's across the board. So we have to be really, really careful to understand dosing and I think that is the biggest obstacle to overcome. One more thing I'm going to say in this in Canada, for instance so Canada is a completely better than legal country they have specific guidelines on marketing advertising. You can't market advertise a cannabis product, so people buy their products based on the percentage of THC. The more THC you have, the perception is the better the product is, or the better bargain you're getting, because, hey, I'm getting 100 milligrams of THC versus 10 or something like that. And this is not the way to be able to communicate to people what an efficacious product should be. It should be really, really specific. And the last thing I'm going to say on this dosing thing when states went recreational, they started forgetting their medicinal patients. In California, you can come into a dispensary and you can find almost every kind of concentrate so shatter oil, crystals, you name it high concentrate THC products. But for people that actually have a condition where they need a therapeutic substance, where they need something that's balanced one to one or even CBD four parts to one part THC they're really, really difficult products to find. So we have to actually ask ourselves that, all these programs that we're putting in place and these laws that we're putting in place, are we forgetting the reason why we actually did this in the first place, to help people that have a condition or they want to have a therapeutic wellness substance and those products are less than available for them now.

Yeah, that is interesting. That is interesting that the people that it's intended for, that these laws that were put in the place were intended for, are the ones that are kind of been left behind. That definitely needs to be addressed and thank you for being on the forefront of getting that addressed so that they can address their health issues and seek some relief as well. Now with you have your book Making Cannabis Personal. Can you tell us a little bit about your book?

Yeah, so my book is a little bit of my personal journey. It talks about some of those rallies and then fighting in my own personal story with cannabis, and then it goes into stories of different people, so people that have tried cannabis. I love using grandma Mary. It's one of my favorite stories.

And if we?

have a little bit of time, maybe a minute, I can kind of give you an overview.

Definitely.

Grandma Mary was sitting in an assisted living facility and she was diagnosed with cancer and just started her first treatment of chemo. And she was watching TV and saw Dr Sanjay Gupta talk about cannabis to help alleviate the side effects of chemo. So she decided to go to a dispensary and try it. Now, 50, 60 years ago I don't know how to bed experience with a cannabis brownie, but it was 60 years ago. So she figured hey, why not? So she went through dispensary. She told the bartender there about her previous experience. He gave her a gummy and said grandma, take it easy, don't do more than two. Try one, then take another, but don't take any more than that. So grandma listened one back to the facility, did one, waited about 20 minutes and nothing happened. So she took another one, waited 20 more minutes and then she began to feel very anxious. Her heart started beating and it started getting progressively worse and worse and she had a really, really intense experience. So the onset was much slower. It was much more intense and lasted, what she said, for like almost two days. She had a very, very long experience and very intense experience. So grandma began to say I'm staying away from this and started telling people around her. This is the living facility. Stay away from devil's lettuce. Now, when we did grandma's DNA test, we saw that she had predispositions to a lot of these stress markers that we've mentioned before on FAH and CNR1, et cetera and had this predisposition to psychosis as well. So, the story is, once she realized that she needs a more balanced formulation, something that's more one-to-one, different terapine profile, she would not only did it help her tremendously, but she would actually give out our business card to people when she was getting chemo other people to give them a call and see if we can help alleviate the symptoms of chemo. So that's one of the stories that's in the book of trying to find what's right for you. And if she didn't do that, it would have perpetuated this devil's lettuce kind of thing instead of finding what is the right therapeutic dose for that individual.

Wow, thank you for sharing that story of grandma. Oh, even grandma needs to get some therapeutic relief right from our plants. So with endodna you've created in summer you created the DNA test to help identify what product would be best or not necessarily best, but just to educate, find some patients on.

The way that it actually works. When you get the report, you log into your portal, which is called MyDNAlive, and you look at all the different symptomatic conditions and it's all color coded. So green means there's no variant detected, so there's a variant. And red means multiple variants, so especially higher chance of that symptomatic condition expressing itself. And what you would look at it, it's all categorized. So you have anxiety markers, mood, you have sleep, you have all these different markers and you click on and see what the report is. The report may say you are much more prone to stress reactivity than the average person. Well, guess what? Here a study's shown how higher amounts of THC can actually trigger this epigenic expression. So for you what it may be suggested going for a ratio of maybe 10 to 1 CBD to THC and different terpene profiles. Instead of limonene, which is a dopamine boosting terpene profile, maybe look at linole, which has been shown in studies to help lessen the anxiety than may be provoked by THC. So now that you have your secret sauce, the next thing is dosing, like I mentioned. Then it's drug-to-drug interaction. And then what we do once we have your secret sauce, that you may wanna consume products that are in this category. Now we use a certificate of analysis of the test results of actual products. They're geo-fenced and show you how closely these products match your suggested ratios. So when you actually buy a product now we can come back and say how efficacious is this product, that the platform has suggested, that these are a 90% match for you. And when it goes back to patient-reported outcome and also integration with your wearable device, now AI starts saying there's a thousand people that have a similar genetic profile than you that took this protocol and have reported efficacy, so this is probably the best protocol that's being suggested for you. So it's sort of bookends the experience Okay.

Now. Can you tell us more about that device?

Oh yeah, so any wearable, like your O-ring or your Fitbit or the one I'm wearing right now. These devices measure different things. So they measure blood oxygen level, they measure heart rate variability, measure the quality of my sleep For me. I wear this because sleep is really important for me, so I measure the quality of my sleep. So how much deep sleep am I getting? How much Delta? How much data sleep? So this data can go to the cloud to be able to support the protocol. So if I'm on a protocol to help me sleep, I'm coming back and saying you know what? I slept for nine hours. I feel like I slept really well. But the data the RPG data that's coming from your wearable device goes to the cloud, adds that to the anonymized data based on your patient report or outcome, and then the AI says, okay, well, this protocol also helped with heart rate variability. It helped with blood oxygen level. It helped to get two and a half hours of deep sleep versus one hour of deep sleep that this person was getting before. So for sleep, if that's the condition you want to alleviate, then this protocol is best. So it takes that data, combines it with a PRO and that's how we get that data from wearable devices as well, oh, that's good.

So you're actually tracking the improvement and the outcomes. Definitely that's great. So, with EndoDNA and your book, what other big ideas and projects can you give us a sneak peek into, Mr May?

Lots of big ideas. I also have a podcast called Everything is Personal, that I do so you can find it wherever. But we're moving into whole genome sequencing right now so this is the next 90 days on a roadmap is to move from right now we genotype right under 700,000 polymorphism SNPs we're moving to 64 million and the platform is going to be used as a software, as a service model. So basically, what our partners and our customers are asking for and our customers are not just the end user customers. Our customers are healthcare professionals, our resellers, like other companies that want to use our test and our platform and the white label at and also a global marketplace. So we're in Brazil, we're in Costa Rica and Brazil it's all translated Portuguese. We're in Costa Rica, we're in Mexico we're translating that into Spanish. We are in the UK all of North America, canada as well, australia, and we're just moving into Thailand. So the next iteration is whole genome. Now you'll be able to go in, choose the reports that you want. So you want the endocannabinase system report. Click there and it's your platform. You want the women's health report. You want the men's health report. You want the skin report. You want the full vitamin nutrient. You want the PGX reports, that's what you'd be choosing, and then you'll pay accordingly, based on the reports that you want, and then we'll continue. That is our software goals, that's our corporate goals. And then it's clinical trials. So we wanna get involved in as many clinical research studies as we possibly can, because we feel that a lot of clinical research that's being done is not looking at your pharmacogenomics, it's not looking at your metabolic functions, it's not looking at your genetic predispositions. And the next phase of this is also looking at biological age. So think about being swabbed twice, or maybe even getting enough from saliva, where your whole genome, we have your biological age, and from your biological age you have a protocol that's been suggested to you or been recommended. And here's a protocol of maybe even your hormone optimization, your personalized supplementation, your phytonutrients, so your phyto-canabinoids maybe even have some prescription medication that we haven't decided on that. But then in six months we come back and swab you again and we see if your biological age has decreased. So the mandate that I sort of gave the company is our goal is to see if we can help people decrease their biological age by seven years. And how we do that. First of all, we have to learn your genetic predispositions and then, over time, hopefully machine learning will start making those predictions as well.

Well, thank you for sharing that. I am looking forward to everything that you have coming out with doing the whole genome sequencing now. So big things to come. Well, thank you for joining me on the podcast. It's been a pleasure, Mr May.

I appreciate it. Thank you so much.

Well, that's all I have for you today. If any part of this conversation interests you or resonated with you, we would love to hear your thoughts. Your five-star review and comments can guide others on similar journey and with similar interests. Subscribe, rate and download this episode to ensure you're always in the loop, and check out the show notes for Mr May's information Coming at next week. On the show, I have a special guest who will give us some pointers on how to create a powerful thought leader brand so you can scale your business and attract your ideal client. So tune in next Friday. Until then, always remember in your journey as a healthcare professional, always raise the script on health, because together we can bring healthcare to higher levels. Have a great day.